‘Don’t mistake tumour markers for cancer screening’: Oncologist explains why
Source Entity
The Indian Express
A Dubai-based longevity clinic recently suggested that people include annual tumour marker tests—such as CEA, CA-125, AFP, CA 19-9 and PSA in their routine health check-ups to detect cancer early. Bu...
The Danger of Misinterpreting Tumor Markers in Preventive Care
In a recent development highlighting the tension between the burgeoning 'longevity' industry and evidence-based oncology, a Dubai-based clinic has come under scrutiny for promoting annual tumor marker tests as a routine part of cancer screening. The clinic suggested that testing for markers such as CEA, CA-125, AFP, CA 19-9, and PSA could help detect cancer early. However, medical experts, specifically oncologists, have stepped forward to correct this narrative, warning the public that these tests are not designed for general population screening and can lead to significant medical mismanagement.
Understanding Tumor Markers: Tools, Not Screens
Tumor markers are substances—often proteins—produced by cancer cells or by the body in response to the presence of a tumor. While they are invaluable in specific clinical contexts, their utility as a primary screening tool is severely limited. For instance, markers like CEA (Carcinoembryonic Antigen) or CA-125 are frequently used to monitor how a patient is responding to chemotherapy or to detect if a known cancer has returned. The critical distinction lies in the difference between monitoring and screening. Screening implies testing an asymptomatic person to find a disease, whereas monitoring involves tracking a known condition. When applied to healthy individuals, these markers often lack the sensitivity and specificity required to provide a reliable diagnosis.
The Peril of False Positives and Over-Diagnosis
One of the primary concerns raised by oncologists is the high incidence of false positives. Many tumor markers can be elevated due to non-cancerous conditions. For example, inflammation, benign cysts, or even common infections can cause a spike in markers like CA-125 or PSA. When a longevity clinic promotes these as 'cancer screens,' a slightly elevated result can trigger an avalanche of unnecessary and invasive follow-up procedures. Patients may be subjected to stressful biopsies, high-radiation CT scans, or exploratory surgeries to find a tumor that doesn't exist, leading to physical harm and profound psychological distress.
The Rise of the Wellness and Longevity Industry
This incident reflects a broader global trend where 'longevity clinics' and 'wellness centers' prioritize comprehensive testing packages over targeted, evidence-based medicine. By offering exhaustive panels of blood tests, these clinics often market a sense of 'total control' over one's health. However, this approach often ignores the clinical guidelines established by global health organizations. The push for 'annual tumor marker tests' is frequently driven more by commercial interests and the desire to provide a 'premium' service than by clinical efficacy, creating a gap between marketing promises and medical reality.
Future Directions in Early Detection
While traditional protein-based tumor markers are insufficient for screening, the field of oncology is moving toward more precise methods. The development of 'liquid biopsies,' which detect circulating tumor DNA (ctDNA) or exosomes in the blood, offers a more promising path for early detection than the markers promoted by the Dubai clinic. These newer technologies aim to identify genetic mutations specific to cancer, potentially reducing the false-positive rates that plague traditional markers. Until these technologies are standardized for general use, experts insist that screening should remain focused on proven methods, such as mammograms, colonoscopies, and low-dose CT scans for high-risk smokers.
Conclusion
The warning from the oncology community serves as a vital reminder that 'more testing' does not always equal 'better health.' The misuse of tumor markers for routine screening can lead to a cycle of over-diagnosis and unnecessary medical intervention. For the general public, the most effective strategy for cancer prevention remains a combination of lifestyle modifications and adherence to clinically validated screening schedules based on age, genetics, and risk factors, rather than the generalized panels offered by longevity clinics.